Furthermore, the identified tear cytokine profiles, particularly those distinguishing between GVHD and non-GVHD patients post-HSCT (M-CSF, FGF1, Fas-L, and PDGF-CC), could serve as objective biomarkers for disease activity. This evidence concerns the gene FGF1 and graft versus host disease.